THE recognition of the importance of the sympathetic nervous system in the control of the systemic arterial blood pressure has stimulated the search for therapeutically useful sympathoadrenergic blocking agents that may be of use in the diagnosis and treatment of hypertensive vascular disease. Numerous agents of diverse chemical structure have been developed and explored for such therapeutic effectiveness but few have proved to be of any clinical value.
Among those, however, that have achieved a place in clinical practice is phentolamine, a drug of the imidazoline group, chemically related to both tolazoline (Priscoline) and histamine. This agent has been shown to cause both adrenergic and sympathetic blockade in animals' 5 and in man.2 9 These latter authors all reported that a considerable reduction in systemic arterial pressure resulted from the parenteral administration of the drug to both hypertensive and normal subjects, and the majority remarked particularly on its orthostatic effects.
The initial hope that the chronic oral administration of the drug would be of practical use in the treatment of hypertensive dis-ease2' 10 was not borne out in later reports due to the production of intolerable gastrointestinal side effects by the preparation and the rapid development of refractoriness to its antihypertensive properties.9 However, due to its supposed propensity in blocking the effects of circulating catecholamines, the drug rapidly achieved eminence as a routine biological screening test for pheochromocytoma."-'7 Nevertheless, the rapid waning of interest in its use as a practical antihypertensive agent no doubt largely accounts for the absence of any comprehensive study of its circulatory effects in man.
Our interest first centered on phentolamine during the search for an effective catecholamine-blocking drug as part of wider study of the role of the autonomic nervous system in the control of blood pressure in normal man and in patients with hypertensive vascular disease. Although the drug has been found to have circulatory effects that preclude its usefulness in this particular respect, the continued widespread use of the drug as a routine diagnostic screening test for pheochromocytoma in hypertensive disease prompted the consideration that the findings would be of some general interest. The following report, part of a detailed study of the circulatory effects of the drug, concerns an analysis of the hemodynamic effects of the acute intravenous injection of phentolamine in normal subjects and patients with hypertensive disease.
Methods

Clinical Data
Studies were made on six normal subjects and six hypertensive patients; details of each individual are listed in tables 1 and 2. All the hypertensive patients were considered to be suffering from uncomplicated essential hypertension on the basis of the usual diagnostic clinical criteria. None had any symptoms referable to the cardiovascular system except patient A.A., who had mild exertional dyspnea. In five of the six patients the resting aortic diastolic pressure, recorded in the supine position at the time of the study exceeded 120 mm. Hg. In four of the hypertensive patients there was no radiologic or electrocardiographic evidence of left ventricular enlargement. In the remaining two patients (A.S. and A.A.) there was radio-logic evidence of cardiac hypertrophy without dilatation, and in both instances this was associated with electrocardiographic changes indicative of moderate left ventricular hvpertrophy. The optic fundi were without papilledema, hemorrhages, or exudates in all six hypertensive patients. Routine tests of renal function were within normal limits in all six patients, and renal arteriographs showed no evidence of renal vascular disease in any patient. The 24-hour urinary excretion of vanillyl-mandelic acid was within normal limits in all the hypertensive patients.
Plan of Investigation
The investigation was designed to study the general hemodynamic changes following the abrupt intravenous injection of phentolamine, as usually used in the clinical diagnostic procedure.
In all individuals, systemic arterial pressure, cardiac output, and heart rate were measured during a control period of 10 minutes and then for a further 30 minutes after the rapid intravenous injection of 5 mg. of phentolamine in a volume of 2 ml.; the injection was completed within 2 seconds. Systemic arterial pressure and heart rate were monitored continuously throughout the study. Cardiac output was determined on alternate minutes during the control period, every minute for the 6 minutes after the injection of the drug, and then on alternate minutes again for the remainder of the study. Oxygen uptake, derived from the product of the blood oxygen arteriovenous oxygen content difference (AV diff.) and cardiac output, was determined at minute or alternate minute intervals, at the same frequency as the measurements of cardiac output. Due to the possibility that the circulatory changes may in part have been due to possible hypoglycemia, serial estimations of the blood sugar were made throughout the period of observation in two of the normal subjects (L.D. and J.A.) and two of the hypertensive patients (A.A. and J.N.). The injection of phentolamine, 2-(N-p-tolyl-N-m-hydroxyphenyl-amino-methyl)-imidazoline, was given as the methane sulfonate salt.
Laboratory Technics
Laboratory air temperature was controlled at 23 C, in all studies; the relative humidity varied between 50 and 70 per cent between different studies.
Following prior familiarization with the plan of the procedure, the laboratory surroundings, and the personnel involved, all patients were studied in the supine position in the fasting state without sedation.
Previous studies have demonstrated that a rnore basal and stable circulatory state may be induced in patients under investigation by a short period of nonfatiguing leg exercise. 18 In the present study, therefore, the definitive control observations were commenced 20 minutes after completion of a 5-minute period of light leg exercise.
Systemic arterial pressure was taken through a Nylon catheter, bore 0.80 mm., length 55 cm., introduced percutaneously into the brachial artery by a modified Seldinger technic and advanced into the aortic root. Pressures were transduced by a Statham P23Db strain-gage manometer. The catheter-manometer system was critically damped to give a virtually flat frequency response to 20 cycles per second. The square wave response of the system was 95 per cent within 0.03 second, with less than 5 per cent overshoot. The electrical output from the manometer was arranged to allow synchronous recording of both pulsatile and mean aortic pressures. The systemic arterial calibration was arranged to extend approximately 10 mm. Hg on either side of the aortic pulse pressure to allow maximum recording precision with the least electromechanical distortion. The saline-filled calibration pressure heads for the system were maintained by specially calibrated Reckla anaeroid manometers. Zero reference level of the manometer was 10 cm. above the plane of the x-ray table, the manometer and pressure heads being fixed at this level.
Cardiac output was determined by an indicatordilution technic employing indocyanine green.
Precisely known amounts of the dye, approximately 2 mg. in 1.5 ml. of volume, were injected into the pulmonary artery through one lumen of a triple-lumen cardiac catheter by a rapid-action electrically activated compressed-air driven syringe-pump, each injection being completed within 0.3 second. The dve-dilution curves were taken from the aortic root through a second arterial catheter of identical dimensions to that used for arterial pressure measurement. Blood was withdrawn through the cuvette at a sampling rate of 38 ml. per minute by a constant-speed syringe-type Harvard pump. The dye curves were transcribed by a Waters X300A cuvette densitometer in conjunction with an ultraviolet recorder. By this technic duplicate determinations of cardiac output, carried out under strictly controlled conditions of circulatory stability have been shown to differ by less than 2 per cent. The standardization and precision of this dyedilution method are being reported elsewhere.'9 The heart rate was determined from a continuously recorded electrocardiographic tracing.
All analogue tracings were recorded on a multichannel ultraviolet recorder (New Electronic Products Ltd., Type 1185) using galvanometers Circulation, Volume XXXI, May 1965 of 35-cm. focal length and a distortion-free deflection arc of 10 cm., arranged as previously described. 18 The frequency response of the galvanometers used for recording the intravascular pressures was 90 cycles per second at -95 per cent of true fidelity.
Mixed venous blood samples were taken from the pulmonary artery and systemic arterial blood samples from the aorta. Both groups of samples were analyzed for percentage oxygen saturation by a standardized hemoreflector technic calibrated against the Van Slyke method.'9 Arterial blood samples were also used to determine the blood oxygen capacity by a standardized spectrophotometric technic.19 Blood sugar determinations were made by the method of Huggett and Nixon.20 Measurements and Calculations Intravascular pressures and heart rate were measured as the average of the 15-second values falling equally about the definitive point. Cardiac outputs were measured by conventional integration technics, the final 10 per cent only of the downslope requiring to be replotted according to the Hamilton semilogarithmic extrapolation method. The calculation of the mean systemic vascular resistance was modified to incorporate a correction for the body surface area, the arguments for which have been discussed elsewhere.'8 The oxygen uptake was derived as the product of the cardiac output and arteriovenous oxygen difference. The validity and precision of this method have been established by comparison of the dye-dilution method as used in the present study with a standardized Fick meth- od. 19 Statistical analyses were based on orthodox methods.21 Description of the significance of changes due to the drug was based on the method of comparison of differences between the means of small samples. In the present study the statistical significances given for each parameter relate to the differences between the average of the control values and that at the stated time.
Results
The individual values of the primary measurements and derived data are detailed in tables 1 and 2 and illustrated in figures 1 to 6. The percentage differences between the average control value and that obtaining at the first minute after injection of the drug for each parameter in each subject are detailed and summarized in table 3.
Clinical Effects of the Acute Injection of Phentolamine
None of the normal subjects nor any of the hypertensive patients complained of symptoms due to the acute injection of the drug, despite considerable reductions in the systemic blood pressure and increases in heart rate following its intravenous injection. The electrocardiogram showed no significant change during the study in any individual. This is of particular importance in view of the myocardial ischemia that may follow the in-L.D. Hemodynamic efects of an acute injection of phentolamine in three normal subjects.
travenous injection of the drug and in view of its myocardial effects.22
Changes in Systemic Arterial Blood Pressure
The acute intravenous injection of 5 mg. of phentolamine was immediately followed by an abrupt reduction in blood pressure in all subjects. The systemic arterial pressure started to fall within 15 seconds of completion of the injection and had reached its lowest value within 1 minute in all normal subjects and hypertensive patients alike. The average reduction in mean arterial pressure was 15 mm. Hg (range of reduction 13 to 20) and 34 mm. Hg (range of reduction 18 to 55) in the normal subjects and hypertensive patients, respectively. These values, expressed as a percentage of the average preinjection levels of pressure, represent reductions of 14 per cent (p<O.OOl) and 20 per cent (p<0.001) respectively in the two groups. Thereafter the systemic blood pressure gradually returned toward preinjection levels, although the pattern of recovery varied considerably between different subjects (figs. 1 to 4).
With regard to the criteria usually employed in clinical practice to interpret the changes in blood pressure, the intravenous injection of phentolamine was followed by a prompt reduction in systemic arterial pres-sure in all subjects, and in no instance was a preceding hypertensive response observed. In three of the six hypertensive patients (J.W., A.S., and F.E.) the maximum reductions in systolic pressure were 53, 94, and 36 mm. Hg and in diastolic pressure 39, 41, and 27 mm.
Hg, respectively. The reduction in systolic pressure exceeded 35 mm. Hg for 3 minutes and the diastolic reduction exceeded 25 mm. Hg for 2 minutes in all three patients. These values are all appreciably in excess of those usually used to define a positive response to the drug. None of these patients had any evidence of an excess of circulating catecholamines, none was sedated, and none had any clinical condition that might have predisposed to such false-positive results.
In all but one (K.J.) of the normal subjects, the reduction in mean systemic arterial pressure that followed the injection of phentolamine was accompanied by a small increase in pulse pressure. However, all of the hypertensive patients exhibited considerable reductions in arterial pulse pressure after the drug. The 
Figure 3
Hemodynamic effects of an acute injection of phentolamine in three hypertensive patients.
arterial pressure. No similar correlation between changes in pulse pressure and cardiac output was observed in the hypertensive group of patients (r = 0.510, p < 0.10). In this group, likewise, the changes in pulse pressure were not directly related to changes in mean arterial pressure or stroke volume.
Changes in Heart Rate, Cardiac Output, and Stroke Volume
The fall in systemic arterial pressure that followed the rapid intravenous injection of phentolamine was followed in all subjects by a somewhat less prompt increase in heart rate and cardiac output without large or consistent changes in stroke volume (table 3) . Although the magnitude of the changes in all three parameters was essentially similar in both groups of subjects, the time course of their response was significantly different (figs. 1 to 4). Whereas in the majority of the normal subjects the maximum changes in heart rate and cardiac output occurred within one minute of the injection, in the hypertensive subjects the corresponding maximum values were not achieved until the third minute after the drug. The average maximum increase in heart rate was 21 beats per minute (range of increase 12 to 24; p < 0.001) and 25 beats per minute (range Circulation, Volume XXXl, May 1965 of increase 20 to 35; p < 0.001) in the normal and hypertensive groups of subjects, respectively. The corresponding average maximum increases in cardiac output in the two groups were 0.779 L./min./M.2 (range of increase 0.340 to 1.472; p <0.010) and 0.911 L./min./ M.2 (range of increase 0.725 to 1.184; p < 0.001), respectively. The attainment of the peak increase in heart rate and cardiac output was immediately followed by a gradual reduction in these values toward preinjection levels in both groups of subjects. However, whereas the heart rate and cardiac output had returned to preinjection control values in all of the normal subjects within 30 minutes, and in all but one (M.N.) within 20 minutes, the return toward normal values was much less rapid in the majority of the hypertensive patients. Both values were still appreciably elevated in four of the six hypertensive patients at 30 minutes after the injection.
Changes in Systemic Vascular Resistance
The systemic vascular resistance was abruptly reduced by phentolamine in all subjects. The maximum fall occurred within the first minute after injection of the drug in all of the normal subjects. In the hypertensive patients the attainment of the maximum fall was slower; in two by the end of the first minute, in two by the end of the second minute, and in the remaining two by the end of the third minute. At the end of the first minute after injection the average reduction in systemic vascular resistance was 750 dyne sec. cm.-5 M.2 (range of reduction 406 to 961) and 1581 dyne sec. cm.-5 M.2 (range of reduction 1205 to 2250) in the normal subjects and hypertensive patients, respectively. However, expressed as a percentage of the initial mean preinjection value, the reductions in systemic vascular resistance were very similar, namely, 29 per cent (p < 0.001) and 34 per cent (p < 0.001),
respectively. The pattern of return of the systemic vascular resistance toward preinjection control values was variable but in general paralleled the pattern of recovery of the systemic arterial pressure. The systemic vascular resistance had returned to control values within 30 minutes of the phentolamine injection in all of the normal subjects but in three of the six hypertensive patients it was still appreciably reduced at this time.
Changes in Oxygen Uptake
The changes in minute oxygen uptake following the injection of phentolamine were fairly consistent within each group of subjects. In both groups of subjects the oxygen uptake during the control preinjection period was within normal limits; the average values were 145 ml./min./M.2 (range 129 to 165) and 148 ml./min./M.2 (range 127 to 177) in the normal and hypertensive groups of patients, respectively. In all of the normal subjects the injection of phentolamine was immediately followed by a rapid reduction in oxygen uptake (fig. 5 ). The maximum reduction occurred at the second or third minute after the injection; the average maximum reduction was 30 ml./min./M.2 (range of reduction 16 to 62; p <0.001). Thereafter the oxygen uptake progressively increased toward preinjection levels, which were attained in all six normal subjects within 20 minutes of the injection. The average total oxygen deficit due to the drug in these subjects compared to the preinjection levels of oxygen uptake was 208 ml./M.2 (range of deficit 63 to 451). In none of the subjects was a subsequent increase in oxygen uptake observed within the period of observation. In the group of hypertensive patients the changes in oxygen uptake following injection of the drug were more varied ( fig. 6 ). In three of the patients (J.W., A.S., and F.E.) reductions in oxygen uptake of 24, 19, and 15 Efect of an acute injection of phentolamine on the oxygen uptake in six normal subjects.
at the second minute after the injection of the drug. Subsequently, the oxygen uptake increased rapidly to exceed the preinjection control value in each of these subjects before gradually returning to prephentolamine levels. In the other three patients (E.B., A.A., and J.N.) the changes in oxygen uptake followed a biphasic pattern, although the main trend was an increase. In the hypertensive patients as a group the net change in oxygen uptake after the drug was an average increase of 94 ml./M.2 (range of increase 16 to 277; p < 0.001).
Changes in Blood Sugar
The changes in blood glucose before and after the injection of phentolamine are detailed in table 4. There was an immediate, small but sustained reduction in blood glucose following the injection in both the normal Efect of an acute injection of phentolamine on the oxygen uptake in six hypertensive patients.
subjects and in one (J.N.) of the hypertensive patients. However, the magnitude of the changes were such as to be unlikely to have resulted in any significant circulatory effects.
Dose-response Relationship
Over the relatively narrow dose range of phentolamine used (0.215-0.392 mg./Kg. of body weight) there was no correlation between the dose of the drug and the systemic arterial pressure response in either group of subjects singly or combined (r = 0.213).
Discussion
These observations indicate that in normal and hypertensive man the immediate circulatory action of phentolamine is to cause an abrupt reduction in the general systemic vascular resistance, resulting in a rapid fall in systemic blood pressure in spite of an increase in the cardiac output. The evidence that the immediate and predominant hemodynamic effect of phentolamine is to reduce the peripheral vascular resistance proportionately throughout the majority if not all of the regional vascular territories, has been presented elsewhere.23 Parallel studies by the same authors have also demonstrated that the central venous pressure falls rapidly at a time when the venous return is very considerably increased, suggesting that the drug was also probably responsible for some degree of venous dilatation.24 In the same study certain findings were also observed suggesting a sim- ilar vasodilator activity of the drug on the pulmonary circulation. In fact, in these latter studies it was demonstrated that the acute injection of phentolamine also resulted in a rapid but transient shift of blood volume from the systemic to the pulmonary vascular bed.24 Such a transfer of blood would certainly potentiate the immediate direct hypotensive activities of the drug. The evidence from this and other studies would suggest therefore that the drug has potent vasodilator activities. The rapidity and magnitude of the reduction in the systemic vascular resistance of both normal and hypertensive patients equally would likewise suggest that the predominant mode of action of the drug involved in this particular response was due to a direct musculotropic vasodilator effect on the resistance vessels of the systemic circulation. Collateral evidence lends strong support to this contention. Phentolamine appears to have only a weak sympathetic blocking activity4 which is insufficient to affect appreciably the vasoconstriction of the upper limbs during supine leg exercise in man25 or to block the Valsalva response.6 23 However, this weak sympathetic-blocking activity of the drug is combined with a much greater propensity to block the hemodynamic effects of circulating catecholamines. In animals its activities in this respect were 30 times as great as its sympathetic blocking effects,4 and the present authors have demonstrated a similar activity in man. 26 Further, the absence of any overshoot of the systemic arterial pressure after the injection of the drug, compared to the not infrequently marked overshoot after a similar reduction in pressure with histamine, may well be due to antagonism of the catecholamines reflexly discharged in response to the abrupt hypotension. However, this moderately powerful antagonism of the circulatory effects of the endogenous catecholamines is completely overshadowed by the considerably more potent direct vasodilator activities of the drug. It is predominantly to this latter property that phentolamine owes its hypotensive reputation.
These foregoing considerations would sug-Circulation, Volume XXXI, May 1965 gest that the mechanism of the hemodynamic changes that are observed following the intravenous injection of the drug is threefold: firstly, by producing a small degree of blockade of sympathetic nervous activity; secondly, and more importantly, by producing a moderate degree of antagonism to circulating catecholamines; and lastly, and of the greatest proportional magnitude, by causing a generalized direct vasodilatation of all muscular-walled vessels both small and large in all vascular territories.
In the studies previously referred to, evidence was presented suggesting that the drug not only caused a considerable dilatation of the peripheral arterioles but also possibly of the major muscular arteries.23 It is well known that the state of contraction and resistance to stretch of the muscular carotid arteries are the primary factors affecting the receptors responsible for reflex regulation of the arterial pressure in this region. Under normal conditions, a reduction in blood pressure results in an immediate reflex response from these receptors in an attempt to reverse the fall, by peripheral vasoconstriction, tachycardia, and an increase in cardiac output. A drug that not only lowers the blood pressure but also dilates the muscular arterial wall could therefore be expected to result in an extremely brisk reflex hemodynamic response. Experimental evidence in direct support of this contention is forthcoming from two sources. The intravenous injection of phentolamine in dogs in comparable doses to those used in the present study caused a marked sensitization and potentiation of the carotid sinus reflexes.4 Further, Martini and Rovati27 found that the local application of phentolamine to the carotid sinus of the dog likewise resulted in a marked potentiation of the reflex pressor response to carotid hypotension. It would appear, therefore, that not only is the afferent pathway of the pressor reflex unaffected, as judged by the hemodynamic response to exercise,25 but also that the drug certainly does not depress the reflex activity of the sinoaortic receptors. While there is no direct evidence from this or other studies of a direct depres-sor effect of the drug on the higher centers of vasomotor regulation, such a possibility would explain the observed effects. The small molecular size of the drug and the rapidity with which it achieves its circulatory effects would certainly be consistent with rapid intracellular transport throughout the body tissues, including those of the central nervous system.
In this respect it is of interest to speculate briefly on the biological cellular activity of the drug. A reduction in oxygen uptake due to phentolamine does not appear to have been previously reported. In the present study all of the normal subjects showed significant if transient reductions in oxygen uptake: it is possible that a similar effect in the hypertensive patients was obscured by the much larger increase in cardiac work in these subjects following the injection of the drug. The relatively rapid time course of this depression of oxygen uptake considered in conjunction with the fact that under normal resting conditions the level of circulating catecholamines is extremely small28 would tend to exclude catecholamine antagonism alone as a reliable cause of this effect. Imidazoles as a group appear to possess the property of being able to block a large number of vital esterase reactions in vivo. 29 The time course of the reduction in oxygen uptake in the present study vould suggest that a generalized but evanescent reduction in cellular oxidative processes may possibly have resulted from injection of the drug.
The majority of antihypertensive drugs in clinical use at the present time exert their major therapeutic effects by blockade of the autonomic nervous system. These drugs have achieved widespread popularity in spite of the fact that they severely compromise those fundamental circulatory adaptations on which such patients particularly depend. Drugs with an imidazoline ring, among which are included phentolamine, Priscoline, and histamine, all appear to possess powerful antihypertensive effects due to their direct depressor activity on vascular smooth muscle. In addition these drugs appear to leave the sympatheti-cally mediated compensatory reflexes of the circulation largely intact. It is somewhat surprising, therefore, that their apparently ideal antihypertensive properties have not been more fully exploited therapeutically.
With regard to the diagnostic use of the drug in clinical practice, its continued popularity as a reliable screening test for pheochromocytoma depends entirely on the interpretation that can be placed on the immediate blood pressure changes observed in the individual patient. The usually accepted values for positive responses are immediate reductions of 35 and 25 mm. Hg in the systolic and diastolic pressures, respectively. In the present study falls in blood pressure considerably in excess of these figures were observed in 50 per cent of the hypertensive patients, none of whom had a pheochromocytoma or other evidence of an increased secretion of catecholamines. Although such a high proportion of false positive reactions has no bearing on the reliability of the test in patients with a definite pheochromocytoma, it seriously impedes the validity of the procedure as a reliable screening test. This is not surprising in view of the in-built fallacy of the test in depending on absolute levels of blood pressure reduction. The drug produces a generalized and relatively nonspecific vasodilatation, so that the percentage reduction in blood pressure was of a comparable order between different individuals. Thus, the higher the absolute level of blood pressure, the greater is the fall after the drug.
In view of these findings, the place of phentolamine as a valid diagnostic test requires serious reappraisal. The value of any drug used in a biological test depends entirely on the precision with which the results can be interpreted. In the case of phentolamine, it is well known that sedatives, uremia, pregnancy, a variety of neurologic diseases, and even a distended urinary bladder all greatly influence the circulatory response to the injection of the drug. In addition, the drug not infrequently causes an unexpectedly large hypotensive response, when none of these factors is apparently operative to explain such Circulation, Volume XXXI, May 1965 an exaggerated effect. This, in fact, occurred in two hypertensive patients in a parallel study.23 These abnormal and often dangerous reactions are probably due to the fact that the diagnostic test, as usually employed, is not, and often cannot be carried out under conditions of uniform biological baseline stability. Under such varied conditions, it is not so surprising, therefore, that injection of a drug which not only blocks two of the important factors responsible for the reflex regulation of the blood pressure, but also achieves its major hemodynamic effect by a powerful direct vasodilator action at arteriolar level, should be instrumental in producing falsepositive results. This contention is supported circumstantially by the finding of a poor doseresponse relationship in terms of blood pressure changes, not only in the present study but also in other reports.23' 30 A further point of considerable relevance is that the onset of left ventricular insufficiency is associated with a progressive increase in vasoconstriction of the regional territories, partly directly sympathetically mediated and presumably potentiated by an increased secretion of adrenal medullary catecholamines. The exhibition of phentolamine under these conditions may produce a profound and misleading fall in blood pressure, due not only to the blockade of these vital compensatory mechanisms, but due to the marked potentiation of its hypotensive properties by an impaired cardiac output responsiveness. These considerations lead one seriously to question the validity of the continued use of the drug as a reliable screening test for the presence of excessive circulating catecholamines due to pheochromocytoma in man.
Summary
Circulatory observations have been made on six normal subjects and six hypertensive patients before and after the acute intravenous injection of 5 mg. of phentolamine.
The drug caused a prompt reduction in systemic vascular resistance which resulted in a rapid fall in systemic blood pressure in spite of an increase in heart rate and cardiac output.
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Evidence is presented that the predominant vascular activity of the drug is to cause a direct relaxation of vascular smooth muscle, an effect far more potent than its antagonism of circulating catecholamines or its very much weaker sympathetic-blocking action. This direct depressor effect on vascular smooth muscle unaccompanied by any but slight sympathetic blocking activities endows the drug with theoretically ideal antihypertensive properties.
Phentolamine caused a transient but significant reduction in oxygen uptake in the majority of individuals. It is suggested that this may be due to a direct inhibition of cellular oxidative mechanisms.
An appraisal of the circulatory activities of the drug with particular regard to its use as a diagnostic test for pheochromocytoma leads to serious doubts, not only with regard to the precision with which the results of such tests can be interpreted, but also to the validity of the use of the drug as a reliable screening test for excessive circulating catecholamines.
